allicin has been researched along with Cancer of Pancreas in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Han, J; Shen, DW; Tang, L; Wang, C; Wang, CJ; Wang, YK; Xu, RH; Zhang, H; Zhao, Y | 1 |
Akbarsha, MA; Chhabria, SV; Desai, KB; Kharkar, PS; Li, AP | 1 |
2 other study(ies) available for allicin and Cancer of Pancreas
Article | Year |
---|---|
Effect of combined treatment with recombinant interleukin-2 and allicin on pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Disulfides; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Humans; Interferon-gamma; Interleukin-2; Killer Cells, Natural; Lymphocyte Count; Mice; Pancreatic Neoplasms; Recombinant Proteins; Sulfinic Acids; Survival Analysis; T-Lymphocyte Subsets; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
In situ allicin generation using targeted alliinase delivery for inhibition of MIA PaCa-2 cells via epigenetic changes, oxidative stress and cyclin-dependent kinase inhibitor (CDKI) expression.
Topics: Antibodies, Monoclonal; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Agents; Apoptosis; Carbon-Sulfur Lyases; Caspase 3; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor Proteins; Disulfides; DNA Damage; Epigenesis, Genetic; Gene Expression; Humans; Oxidative Stress; Pancreatic Neoplasms; Reactive Oxygen Species; Sulfinic Acids; Tubulin | 2015 |